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Mutations in the Mitochondrial tRNA Ser(UCN)
and in the GJB2 (Connexin 26) Gene Are Not
Modifiers of the Age at Onset or Severity of Hearing
Loss in Spanish Patients with the 12S rRNA
A1555G Mutation
To the Editor:
Late-onset deafness is likely to be the result of complex
interactions between genetic susceptibility factors and
the environment. Although enormous progress is being
achieved in the identification of genes that cause con-
genital deafness, less is known about the progressive
forms of hearing loss. The A1555G mutation in the mi-
tochondrial 12S rRNA has been associated with amin-
oglycoside-induced and nonsyndromic sensorineural
deafness (Prezant et al. 1993). We have demonstrated
(Estivill et al. 1998b) that the A1555G mutation is also
present in a large proportion of families and patients
with deafness who were not treated with aminoglyco-
sides; it has also been shown (Torroni et al. 1999) that
many independent origins account for the high fre-
quency of this mutation in patients with hearing loss.
The difference in the expression of the deafness phe-
notype in families with the A1555G mutation could be
explained by different levels of exposure to environ-
mental agents, other than aminoglycosides, that have not
yet been determined. However, it could also be due to
additional mutations in a nuclear gene, to other variants
in the mitochondrial DNA, or, more likely, to complex
interactions of genetic and environmental factors.
To date, efforts to identify a nuclear gene acting as a
modifying factor for deafness in patients with the
A1555G mutation have not been successful (Guan et al.
1996; Bykhovskaya et al. 1998). Recently, Pandya et al.
(1999) demonstrated the coexistence of two mitochon-
drial mutations—G7444A in the tRNA Ser(UCN) and
A1555G—in Mongolian students who were deaf. They
suggested that patients with both mutations in the mi-
tochondrial DNA may present earlier onset and an in-
creased severity of hearing loss than other patients with
the A1555G mutation alone. They proposed digenic
epistasis for A1555G and G7444A, especially in the ab-
sence of aminoglycoside exposure.
We have studied the relationship between A1555G
and other mutations in the mitochondrial DNA affecting
the tRNA Ser(UCN) and mutations in exon 2 of the
connexin 26 gene, for which a high carrier frequency
has been described in theMediterranean population (Ze-
lante et al. 1997; Estivill et al. 1998a; Gasparini et al.
2000). After analyzing 42 unrelated families with the
A1555G mutation, we report evidence that these genes
do not modify the severity and age at onset of hearing
loss in Spanish patients.
In an earlier work we identified 19 families with ma-
ternally transmitted deafness that had the A1555G mu-
tation (Estivill et al. 1998b). Nowwe have collected data
on 139 new families with sensorineural hearing loss: 109
multiplex families (43 families with compatible auto-
somal dominant hearing loss, 53 with compatible au-
tosomal recessive hearing loss, and 13 with maternally
inherited hearing loss) and 30 simplex families. These
new families were tested for the A1555G mutation, as
described elsewhere (Estivill et al. 1998b). We found the
A1555G mutation in 23 of these families (11 maternally
inherited, 7 autosomal dominant, 2 autosomal recessive,
and 3 sporadic). By combining the families presented
here with those described earlier, we identified a total of
209 families with deafness, 42 (20%) having the
A1555G mutation. Of these 42 families, a diagnosis of
deafness was established in 338 of 668 subjects (50%)
with the mutation, indicating an incomplete penetrance
of the A1555G mutation, in agreement with our earlier
observations (Estivill et al. 1998b). The age at onset of
deafness in these patients ranged widely (0–65 years).
Only ∼20% of patients with the A1555G mutation and
deafness were treated with aminoglycosides prior to their
hearing loss. Negative data about treatment with ami-
noglycosides were obtained from the patients and their
parents. This negative history included being given any
drug by injection or having undergone major surgery.
These data indicate the strong role of factors other than
antibiotics in the development of deafness.
We have analyzed the presence of mutations in the
mitochondrial tRNA Ser(UCN) gene by digestion with
the XbaI restriction enzyme, as described by Reid et al.
(1994). Loss of the XbaI site can be due to mutations
A7443G and A7445C, described by Pandya et al.
(1999); to mutation G7444A, reported in association
with Leber’s Hereditary Optic Neuropathy (Brown et al.
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1995); or to mutation A7445G, initially identified in a
Scottish pedigree with sensorineural hearing loss (Reid
et al. 1994). We have not detected any of these changes
in a total of 42 unrelated patients with hearing loss,
representing all of the A1555G-positive families, nor in
112 additional deaf patients with A1555G from these
families (a total of 154 subjects with hearing loss who
were ages 0–65 years at the onset of their deafness). In
contrast with previous findings about deaf students from
Mongolia (Pandya et al. 1999), the G7444A mutation
was not associated with A1555G in the 42 Spanish fam-
ilies with deafness. Thus, G7444A is unlikely to be a
modifier of the wide clinical variability of the deafness
phenotype due to the A1555G mutation in Spanish
patients.
Mutations in the connexin 26 gene (GJB2) are found
in a large proportion of patients with autosomal reces-
sive and dominant deafness (Kelsell et al. 1997; Zelante
et al. 1997; Denoyelle et al. 1998). Mutation 35delG in
GJB2 accounts for 41% of deafness with childhood on-
set in European populations (Estivill et al. 1998a). Car-
rier frequencies for 35delG of 1/75 in central and north-
ern Europe and of 1/35 in theMediterranean region have
been found (Gasparini et al. 2000).
We have studied the GJB2 35delG mutation in the
same sample set of 154 deaf patients with A1555G that
were analyzed for tRNA Ser(UCN); the analysis of the
mutation was performed as described in the study by
Rabionet and Estivill (1998). We also analyzed the cod-
ing region of GJB2 (exon 2) in the sample set of 42
unrelated individuals representing each of the A1555G-
positive families by SSCP analysis. We detected only one
family with the 35delG mutation in heterozygosity, in-
cluding four patients also having the A1555G mutation
and two patients with A1555G alone. None of these
individuals was treated with aminoglycosides. All had
moderate deafness, except for the youngest member of
the family (age 16 years) who had the A1555Gmutation
alone. The onset of deafness in the other patient carrying
the A1555G mutation alone was at age ∼20 years,
whereas the onset of deafness in the patients with both
mutations was at ages 16–30 years. Thus, in this family,
35delG mutation does not seem to modify the deafness
phenotype due to the A1555G mutation. No other
changes in the GJB2 gene were found in this sample of
42 unrelated patients with A1555G.
Since the frequency of 35delG was similar in patients
with A1555G (1 in 42) and in the Spanish general pop-
ulation (1 in 40) (Estivill et al. 1998a), it is unlikely that
the GJB2 gene is a major modifier for hearing loss due
to the A1555G mutation in Spanish patients.
In conclusion, we demonstrate that mutations in the
connexin 26 gene or in the mitochondrial tRNA
Ser(UCN) gene are not modifying factors for the wide
variability of the age at onset and severity of hearing
loss in Spanish patients with the A1555G mutation. The
identification of the different agents that participate in
hearing loss in the presence of the A1555G mutation
should help in the understanding of the complex inter-
actions between environment and genes in hearing and
may facilitate the development of prevention and ther-
apeutic interventions.
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